InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,751.07
(
0.90%
)
US TECH 100
19,476.00
(
1.10%
)
Dow Jones
42,352.75
(
0.81%
)
Brent Oil
77.97
(
0.00%
)
Bitcoin
62,651.98
(
0.93%
)
Post# of 253281
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

rogerm

Send PM Follow Ignore
Followers 2
Posts 112
Boards Moderated 0
Alias Born 08/04/2005

rogerm

Re: mcbio post# 208053

Tuesday, 01/17/2017 12:54:41 AM

Tuesday, January 17, 2017 12:54:41 AM

Post# of 253281
The best Alopecia Areata trial result was obtained with oral Ruxolitinib. ACRS appears to be far behind INCY which is running a P2 topical ruxolitinib and CNCE which has a P2 with a oral deuterated ruxolitinib. http://www.investorvillage.com/smbd.asp?mb=18114&mn=596&pt=msg&mid=16391346
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up